Tecovirimat is safe but ineffective as treatment for clade II mpox
The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...
NIH Trial Finds Tecovirimat Ineffective As Monotherapy For Mpox
A NIH-led trial found tecovirimat ineffective in reducing mpox lesion healing time or pain relief. The study was halted in 2024, with findings presented at CROI 2025.
ACTG Presents Data from Mpox Study STOMP at CROI
The results from STOMP reinforce the value of randomized clinical trials during outbreaks of infectious diseases, like mpox,” said Past ACTG Chair Judith Currier M.D., M.Sc. “There was considerable ...
Science Daily1mon
Mpox: Better understanding of tecovirimat resistance
Tecovirimat is the drug most commonly used to treat patients infected with the mpox virus. Unfortunately, it is sometimes ineffective against certain variants of the virus that have mutations in ...
News Medical1mon
Study explains why tecovirimat fails against some mpox strains
Tecovirimat is the drug most commonly used to treat patients infected with the mpox virus. Unfortunately, it is sometimes ineffective against certain variants of the virus that have mutations in ...
Technology Networks2d
Tecovirimat Is Safe but Ineffective as a Treatment for Mpox
The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox ...
Sierra Sun Times1d
NIH Reports Tecovirimat is Safe But Ineffective as Treatment for Clade II Mpox
NIH-sponsored trial data offers further evidence to help inform mpox treatment decisions.
NIH: Siga’s tecovirimat safe, but ineffective as treatment for Clade II Mpox
The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve ...